TITOMIC LIMITED — Share Issue/Capital Change 2024

Dec 10, 2024

Appendix 2A - Application for quotation of securities

==> picture [21 x 22] intentionally omitted <==

Announcement Summary

Entity name

TITOMIC LIMITED

Announcement Type

New announcement

Date of this announcement

Wednesday December 11, 2024

The +securities to be quoted are: Other

Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.

Shares are being issued as deferred consideration in connection with the acquisition of Dycomet Europe BV which completed on 30 November 2021 and was announced on 1 December 2021

Total number of +securities to be quoted

ASX +security		Number of +securities to
code	Security description	be quoted	Issue date
TTT	ORDINARY FULLY PAID	500,000	11/12/2024

Refer to next page for full details of the announcement

Appendix 2A - Application for quotation of securities

1 / 6

Appendix 2A - Application for quotation of securities

==> picture [21 x 22] intentionally omitted <==

Part 1 - Entity and announcement details

1.1 Name of entity

TITOMIC LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1.2 Registered number type

ACN

Registration number

602793644

1.3 ASX issuer code

TTT

1.4 The announcement is

New announcement

1.5 Date of this announcement

11/12/2024

Appendix 2A - Application for quotation of securities

2 / 6

Appendix 2A - Application for quotation of securities

==> picture [21 x 22] intentionally omitted <==

Part 2 - Type of Issue

2.1 The +securities to be quoted are:

Other

Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.

2.2 The +class of +securities to be quoted is:

Additional +securities in a class that is already quoted on ASX ("existing class")

2.3c Have these +securities been offered under a +disclosure document or +PDS? No

2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

Shares are being issued as deferred consideration in connection with the acquisition of Dycomet Europe BV which completed on 30 November 2021 and was announced on 1 December 2021

2.4 Any on-sale of the +securities to be quoted within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of: The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)

Appendix 2A - Application for quotation of securities

3 / 6

Appendix 2A - Application for quotation of securities

==> picture [21 x 22] intentionally omitted <==

Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Additional +securities to be quoted in an existing class

ASX +security code and description TTT : ORDINARY FULLY PAID

Issue date

11/12/2024

Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class? Yes

Issue details

Number of +securities to be quoted

500,000

Are the +securities being issued for a cash consideration?

No Please describe the consideration being provided for the +securities

Shares are being issued as deferred consideration in connection with the acquisition of Dycomet Europe BV which completed on 30 November 2021 and was announced on 1 December 2021

Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted

0.190000

Any other information the entity wishes to provide about the +securities to be quoted

Shares are being issued as deferred consideration in connection with the acquisition of Dycomet Europe BV which completed on 30 November 2021 and was announced on 1 December 2021

The purpose(s) for which the entity is issuing the securities

To pay for the acquisition of an asset

Please provide additional details

Shares are being issued as deferred consideration in connection with the acquisition of Dycomet Europe BV which completed on 30 November 2021 and was announced on 1 December 2021

Appendix 2A - Application for quotation of securities

4 / 6

Appendix 2A - Application for quotation of securities

==> picture [21 x 22] intentionally omitted <==

Part 4 - Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)

+securities subject of this application)
	Total number of
ASX +security code and description	+securities on issue
TTT : ORDINARY FULLY PAID	1,282,378,727
4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)
	Total number of
ASX +security code and description	+securities on issue
TTTAV : OPTION EXPIRING 19-MAR-2027 EX $0.07	2,000,000
TTTAS : SHARE RIGHTS	120,000,000
TTTAT : OPTION EXPIRING 04-DEC-2027 EX nil	142,500,000
TTTAR : OPTION EXPIRING 08-MAY-2026 EX $0.40	22,312,500

4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)

Appendix 2A - Application for quotation of securities

5 / 6

Appendix 2A - Application for quotation of securities

==> picture [21 x 22] intentionally omitted <==

Part 5 - Other Listing Rule requirements

5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1? No

5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1? No

5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? Yes

5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? 500000

5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? No

Appendix 2A - Application for quotation of securities

6 / 6